Ignite Creation Date:
2024-05-05 @ 11:39 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00096798
Status:
COMPLETED
Last Update Posted:
2008-01-17
First Post:
2004-11-15
Brief Title:
Ethyl Eicosapentanoic Acid Ethyl-EPA for Treating Major Depression
Sponsor:
National Center for Complementary and Integrative Health NCCIH
Organization:
National Center for Complementary and Integrative Health NCCIH
Study Overview
Official Title:
A Double-Blind Placebo-Controlled Study of Ethyl Eicosapentanoic Acid Ethyl-EPA in Major Depressive Disorder
Status:
COMPLETED
Status Verified Date:
2008-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to examine the effectiveness of ethyl-eicosapentanoic acid ethyl-EPA an omega-3 fatty acid in treating depression
Detailed Description:
Evidence suggests that omega-3 fatty acids may help reduce symptoms of depression This study will determine whether ethyl-EPA an omega-3 fatty acid can be used safely and effectively to treat major depression
Participants will be randomly assigned to receive either ethyl EPA-containing pills or placebo daily for 8 weeks Each week participants will be asked to complete questionnaires which will be used to assess the severity of their depression
Participants will be randomly assigned to receive either ethyl EPA-containing pills or placebo daily for 8 weeks Each week participants will be asked to complete questionnaires which will be used to assess the severity of their depression
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None